Healthcare was the second-best performer this week, only Real Estate was better. Except for Novo Nordisk, the sector has little to fear from Tariffs and demand is largely non-cyclical. No new issues printed.
• Bayer lost a recent court case in Georgia where a jury awarded $2.1bn in damages. This will be appealed but further reminders of litigation risk are unwelcome for the credit. Last week’s news that the State of Georgia was likely to permit Federal Labelling laws to override local state rules is good but too late for this particular case. In other news, Elliott Management are said to be discussing an activist campaign to gauge interest in Bayer’s Consumer Health Unit. At 3x sales, this could potentially be sold for €18bn. Given that the market cap of Bayer is only €22bn it shows the extent of value destruction due to litigation. We examined the Pharma competitors on an EV/Sales basis and even with Litigation costs considered Bayer is trading on a very low multiple. A vote on Equity issuance will be held on 25th April.
• Fresenius Medical announced a Tender and New Issue mandate. It will print Exp €1bn dual Short 4yr and 7yr with a simultaneous €250m tender for two 2026 bonds.
• Merck & Co was upgraded to Aa3. The curve flattened with he 2054s tightening 4bps.

Find more articles and bullets on these widgets:
Time For Some Progress On Services?

Jorge Liboreiro at Euronews posts on X: "The expected meeting between [European Commission] High Representative [for Foreign Affairs and Security Policy] Kaja Kallas and [US] Secretary of State Marco Rubio has been cancelled, Euronews has learned. Kallas is already in Washington. She will meet with representatives from Congress and Senate and speak at two different events."
